Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 11



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Patient Information Questions: 1 - 9

Date of arrival at RITN center:1 __ __ __ __ - __ __- __ __

Height:2 inches centimeters

Weight:3 pounds kilograms

Ethnicity4

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 5 - 6

Race5

Race detail6

What scale was used to determine the patient’s functional status?

Karnofsky Lansky

7

Karnofsky scale (patient age ≥ 16 years)8

Lansky scale (patient age < 16 years)9

Consent Questions: 10 - 13

Has the patient signed an IRB-approved consent form for submitting research data to the NMDP/CIBMTR?10

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:11 __ __ __ __ - __ __- __ __

Has the patient signed an IRB-approved consent form to donate research blood samples to the NMDP/CIBMTR?12

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:13 __ __ __ __ - __ __- __ __

Co-morbid Conditions Questions: 14 - 76

Were there clinically significant co-existing diseases or organ impairment at time of evaluation?

yes no

14

Source: Blood, 2005 Oct 15;106(8):2912-2919

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

15

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure,
myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

16

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

17

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

18

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

19

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of
transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

20

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

21

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after evaluation

yes no Unknown

22

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

23

Obesity - Patients with a body mass index > 35 kg/m2  at time of evaluation

yes no Unknown

24

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

25

Psychiatric disturbance  - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

26

Pulmonary, moderate  - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

27

Pulmonary, severe  ­ Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at evaluation

yes no Unknown

28

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

29

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica
requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

30

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

31

Breast cancer

yes no

32

Year of diagnosis:33

Central nervous system (CNS) malignancy

yes no

34

(e.g. glioblastoma, astrocytoma)

Year of diagnosis:35

Gastrointestinal malignancy

yes no

36

(e.g. colon, rectum, stomach, pancreas, intestine)

Year of diagnosis:37

Genitourinary malignancy

yes no

38

(e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Year of diagnosis:39

Lung cancer

yes no

40

Year of diagnosis:41

Melanoma

yes no

42

Year of diagnosis:43

Oropharyngeal cancer

yes no

44

(e.g. tongue, buccal mucosa)

Year of diagnosis:45

Sarcoma

yes no

46

Year of diagnosis:47

Thyroid cancer

yes no

48

Year of diagnosis:49

Other co-morbid condition

yes no Unknown

50

Specify other co-morbid condition:51

Was there a history of malignancy (hematologic or non-melanoma skin cancer)?

yes no

52

Acute myeloid leukemia (AML / ANLL)

yes no

53

Year of diagnosis:54

Other leukemia, including ALL

yes no

55

Year of diagnosis:56

Specify leukemia:57

Clonal cytogenetic abnormality without leukemia or MDS

yes no

58

Year of diagnosis:59

Hodgkin disease

yes no

60

Year of diagnosis:61

Lymphoma or lymphoproliferative disease

yes no

62

Year of diagnosis:63

Was the tumor EBV positive?

yes no

64

Other skin malignancy (basal cell, squamous)

yes no

65

Year of diagnosis:66

Specify other skin malignancy:67

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

68

Year of diagnosis:69

Other prior malignancy

yes no

70

Year of diagnosis:71

Specify other prior malignancy:72

Has the patient received radiation therapy at any time?

yes no

73

Was the patient receiving radiation therapy at the time of exposure?

Yes No

74

Has the patient received chemotherapy at any time?

yes no

75

Was the patient receiving chemotherapy at the time of exposure?

Yes No

76

Patient Exposure Questions: 77 - 87

What was the marrow toxic incident type?77

Improvised nuclear device (IND) / military nuclear weapon

Radiological exposure device (RED) (e.g. Open source)

Radiological dispersal device (RDD) (e.g. Dirty bomb)

Nuclear power plant accident

Industrial / workplace accident

Chemical (e.g. Mustard agent)

Unknown

Was the patient pregnant at the time of exposure?

Yes No Unknown

78

(Female only)

Did the patient have internal contamination?79

Yes

No

Not Applicable (e.g. RED)

Unknown

Was external dose estimation from exposure done?80

Yes

No

Not Applicable (chemical)

Unknown

External Dose Estimation (1) Questions: 81 - 86

Was external dose estimation given as a specific value?

Yes No

81

82 Sv Gy cGy

Was external dose estimation given as a range?

Yes No

83

84 - Sv Gy cGy

Specify method used to estimate external dose from exposure85

Lymphocyte depletion kinetics

Time to onset of vomiting

Prodromal symptoms

Chromosome analysis (dicentrics)

Other method

Specify other method:86

Was documentation submitted to the CIBMTR?

Yes No

87

(e.g. dosimetry evaluation/report)

Patient Trauma / Illness Questions: 88 - 132

Did the patient experience any trauma / injuries as a result of the radiation incident?

Yes No

88

Head

Yes No

89

(include brain)

Specify severity90

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Abdomen

Yes No

91

Specify severity92

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Pelvis

Yes No

93

Specify severity94

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Spine

Yes No

95

(include spinal cord)

Specify severity96

Minor

Moderate (potentially life threatening without appropriate treatment) (includes parapelegia)

Severe (potentially life threatening even with treatment) (includes greater paralysis)

Unknown

Cardiothoracic

Yes No

97

(including central vessels)

Specify severity98

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Extremities

Yes No

99

(including extremity vascular)

Specify severity100

Minor

Moderate (potentially life threatening without appropriate treatment)

Severe (potentially life threatening even with treatment)

Unknown

Burns

Yes No

101

(2nd or 3rd degree)

Specify percent of body surface area affected:102 %

Did the patient experience any symptoms following exposure?

Yes No Unknown

103

Nausea

Yes No

104

(without vomiting)

Specify intensity

Mild Tolerable Intense Intolerable Unknown

105

Time of onset of nausea

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

106

Vomiting

Yes No

107

Specify frequency of vomiting108

Occasional (1 time per day)

Intermittent (2-5 times per day)

Persistent (6-10 times per day)

Refractory (>10 times per day or parenteral nutrition)

Unknown

Time of onset of vomiting

<1 hour 1 - 2 hours >2 - 6 hours >6 hours Unknown

109

Anorexia

Yes No

110

Specify degree of anorexia111

Able to eat and drink; reasonable intake

Significantly decreased intake, but able to eat

No significant intake

Parenteral nutrition

Unknown

Diarrhea

Yes No

112

Specify degree of diarrhea113

2 - 3 stools per day

4 - 6 stools per day

7 - 9 stools per day

≥ 10 stools per day

Unknown

Time of onset of diarrhea

<1 hour 1 - 3 hours >3 - 8 hours >8 hours Unknown

114

Gastrointestinal (GI) bleeding

Yes No

115

Fatigue

Yes No

116

Specify degree of fatigue117

Able to work or perform normal activity

Needs assistance for self-care

Unknown

Fever

Yes No

118

Specify fever119

< 38° C / < 100.4° F

38° C ­ 40° C / 100.4° F ­ 104° F

> 40° C / > 104° F for less than 24 hours

> 40° C / > 104° F for more than 24 hours

Unknown

Time of onset of fever

<1 hour 1 - 2 hours >2 - 3 hours >3 hours Unknown

120

Headache

Yes No

121

Specify intensity

Minimal Moderate Intense Unknown

122

Time of onset of headache

<1 hour 1 - 2 hours >2 - 4 hours >4 - 24 hours >24 hours Unknown

123

Confusion / cognitive deficits

Yes No

124

Loss of consciousness

Yes No

125

Neurological deficits

Yes No

126

Specify degree of neurological deficits127

Mild, no significant interference with normal activity

Prominent, significant interference with normal activity

Life threatening

Hypotension

Yes No

128

Other symptom

Yes No

129

Other Symptoms (1) Questions: 130 - 132

Specify other symptom:130

Specify intensity

Minimal Moderate Intense Unknown

131

Time of onset of other symptom

≤30 minutes >30 minutes - 1 hour >1 - 1.5 hours >1.5 - 2 hours >2 - 3 hours >3 - 4 hours >4 - 5 hours >5 hours

Unknown

132

Organ Function Questions: 133 - 167

AST (SGOT)

Known Unknown

133

134 U/L µkat/L

Date sample collected:135 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:136 U/L µkat/L

ALT (SGPT)

Known Unknown

137

138 U/L µkat/L

Date sample collected:139 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:140 U/L µkat/L

Total serum bilirubin

Known Unknown

141

142 mg/dL µmol/L

Date sample collected:143 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:144 mg/dL µmol/L

Serum creatinine

Known Unknown

145

146 mg/dL mmol/L µmol/L

Date sample collected:147 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:148 mg/dL mmol/L µmol/L

Serum albumin

Known Unknown

149

150 g/dL g/L

Date sample collected:151 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:152 g/dL g/L

Amylase

Known Unknown

153

154

Were amylase isoenzymes obtained?

Known Unknown

155

Pancreatic amylase

Known Unknown

156

157 U/L

Salivary amylase

Known Unknown

158

159 U/L

International normalized ratio (INR)

Known Unknown

160

161

Partial thromboplastin time (PTT)

Known Unknown

162

163 seconds

Reticulocytes (uncorrected)

Known Unknown

164

165
x 109/L

Was a bone marrow examination performed?

yes no Unknown

166

Date sample collected:167 __ __ __ __ - __ __- __ __

Complete Blood Count Questions: 168 - 183

Date sample collected:168 __ __ __ __ - __ __- __ __

WBC

Known Unknown

169

170 x 109/L (x 103/mm3)

x 106/L

Was G­CSF given ≤ 7 days before date of test?

Yes No

171

Neutrophils

Known Unknown

172

173 %

Lymphocytes

Known Unknown

174

175 %

Hemoglobin

Known Unknown

176

177 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

178

Hematocrit

Known Unknown

179

180 %

Platelets

Known Unknown

181

182 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

183

Lymphocyte Analyses Questions: 184 - 198

Were lymphocyte analyses performed?

yes no

184

Lymphocyte Analyses (1) Questions: 185 - 198

Date sample collected:185 __ __ __ __ - __ __- __ __

Time:186 Standard time

Daylight savings time

CD3 (T cells)

Known Unknown

187

188 x 109/L (x 103/mm3)

x 106/L

CD4 (T helper cells)

Known Unknown

189

190 x 109/L (x 103/mm3)

x 106/L

CD8 (cytotoxic T cells)

Known Unknown

191

192 x 109/L (x 103/mm3)

x 106/L

CD19

Known Unknown

193

194 x 109/L (x 103/mm3)

x 106/L

CD20 (B lymphocyte cells)

Known Unknown

195

196 x 109/L (x 103/mm3)

x 106/L

CD56 (natural killer (NK) cells)

Known Unknown

197

198 x 109/L (x 103/mm3)

x 106/L

Therapy and Infection Prophylaxis Questions: 199 - 263

Was therapy given?

yes no

199

(Includes therapy and infection prophylaxis)

Therapy and Infection Prophylaxis (1) Questions: 200 - 263

Specify time point when drugs were given200

Since exposure but prior to evaluation (at RITN center)

During or after evaluation (at RITN center)

Indication for which drugs were given

Therapy Infection prophylaxis

201

Systemic antibacterial antibiotics

Yes No Unknown

202

Non-absorbable oral antibiotics

Yes No Unknown

203

Systemic antifungal drugs

Yes No Unknown

204

Amphotericin

Yes No

205

(Fungizone) (non-lipid formulation)

Amphotericin

Yes No

206

(e.g. Abelcet, AmBisome, Amphotec) (lipid formulation)

Caspofungin

Yes No

207

Fluconazole

Yes No

208

Isavuconazole

Yes No

209

Itraconazole

Yes No

210

Micafungin

Yes No

211

Posaconazole

Yes No

212

Ravuconazole

Yes No

213

Voriconazole

Yes No

214

Other systemic antifungal drug

Yes No

215

Specify other systemic antifungal drug:216

Antiviral drugs

Yes No Unknown

217

Acyclovir

yes no

218

Foscarnet

Yes No

219

Ganciclovir (DHPG)

yes no

220

Valganciclovir (Valcyte)

Yes No

221

Valacyclovir

Yes No

222

Other antiviral drug

Yes No

223

Specify other antiviral drug:224

Growth factors

Yes No Unknown

225

G-CSF

yes no

226

GM-CSF

yes no

227

Pegylated G-CSF

yes no

228

TBO-filgrastim (Granix, Teva)

Yes No

229

Other growth factor

yes no

230

Specify other growth factor:231

Corticosteroids

Yes No Unknown

232

Decorporation drugs

Yes No Unknown

233

Aluminum carbonate

Yes No

234

Aluminum hydroxide

Yes No

235

Barium sulfate

Yes No

236

Calcium carbonate

Yes No

237

Calcium gluconate

Yes No

238

Calcium phosphate

Yes No

239

Deferoxamine (Desferal)

yes no

240

Calcium DTPA IV

Yes No

241

Calcium DTPA by nebulizer

Yes No

242

Zinc DTPA IV

Yes No

243

Dimercaprol (BAL)

Yes No

244

Calcium disodium EDTA

Yes No

245

D-Penicillamine

Yes No

246

Potassium iodide (KI)

Yes No

247

Potassium phosphate

Yes No

248

Potassium phosphate, dibasic

Yes No

249

Propylthiouracil

Yes No

250

Prussian blue, insoluble

Yes No

251

Sevelamer

Yes No

252

Sodium alginate

Yes No

253

Sodium bicarbonate

Yes No

254

Sodium glycerophosphate

Yes No

255

Sodium phosphate

Yes No

256

Succimer (DMSA)

Yes No

257

Other decorporation drug

Yes No

258

Specify other decorporation drug:259

RBC transfusion

Yes No

260

Platelet transfusion

Yes No

261

Other therapy

yes no

262

Specify other therapy:263

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

Specify patient height and weight at time of arrival to RITN center:

Performance score at time of evaluation:

History of Malignancy (Hematologic or Non-Melanoma Skin Cancer)

Specify which malignancy(ies) occurred: 

Specify symptoms:

Specify drugs given:

Center: CRID: 

Form 5000 R1.0: RITN Baseline Form

CIBMTR Form 5000 revision 1.0 last updated Monday, December 21, 2015
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 11 / 11